Significance of serum phosphohexose isomerase, hexokinase and aldolase in carcinoma ovary.
The serum phosphohexose isomerase (PHI), aldolase and hexokinase activities have been determined in 36 patients of carcinoma ovary with different clinical stages and in 25 healthy normal female subjects. The serum PHI and hexokinase levels were significantly elevated (P less than .001) in all the stages of malignancy while serum aldolase was significantly elevated only in stages III and IV of malignancy. The enzyme levels showed statistically significant response to therapy in stage II patients. The mean values in patients with progression of the disease were not significantly different.
D005260:Female; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood*; D005956:Glucose-6-Phosphate Isomerase / Q000097:blood*; D006593:Hexokinase / Q000097:blood*; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy
D006593:Hexokinase; D005634:Fructose-Bisphosphate Aldolase; D005956:Glucose-6-Phosphate Isomerase